Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.52 |
| ▸ | TNF | P01375 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.52 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.52 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.52 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.49 |
| ▸ | SMPD1 | P17405 | 4/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL579348 | 0.93 | NPC1 (0.54) | MAPTKDM4EMEN1KMT2A | |
| SCHEMBL6798353 | 0.92 | NPSR1 (0.50) | MAPTSIGMAR1 | |
| SCHEMBL7043742 | 0.91 | BIRC5 (0.49) | PDE4AMAPK1PDE4DTNFLMNA | |
| SCHEMBL277697 | 0.89 | S1PR2 (0.55) | SMPD1 | |
| SCHEMBL579290 | 0.87 | S1PR2 (0.57) | SMPD1 | |
| SCHEMBL2820207 | 0.87 | S1PR2 (0.57) | SMPD1 | |
| SCHEMBL10427981 | 0.87 | S1PR2 (0.57) | SMPD1 | |
| SCHEMBL12328267 | 0.87 | SIGMAR1 (0.51) | PDE4AMAPK1PDE4DTNFLMNA | |
| SCHEMBL29521379 | 0.87 | REN (0.48) | MAPTKDM4ESMPD1 | |
| SCHEMBL2810242 | 0.87 | REN (0.48) | MAPTKDM4ESMPD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9708310-B2 | Phenanthroindolizidine and phenanthroquinolizidine alkaloid having a hydroxyl group on the phenanthrene ring thereof, preparation method and use thereof | CHINA MEDICAL UNIVERSITY (TW) | 2017-07-18 | — | — | US | disclosed |
| US-9676622-B2 | Process for producing hydrogen or heavy hydrogens, and hydrogenation (protiation, deuteration or tritiation) of organic compounds using same | SHIONO CHEMICAL CO., LTD. (JP) | 2017-06-13 | — | — | US | disclosed |
| US-20170152257-A1 | PHENANTHROINDOLIZIDINE AND PHENANTHROQUINOLIZIDINE ALKALOID HAVING A HYDROXYL GROUP ON THE PHENANTHRENE RING THEREOF, PREPARATION METHOD AND USE THEREOF | CHINA MEDICAL UNIVERSITY (TW) | 2017-06-01 | — | — | US | disclosed |
| EP-2252594-B1 | 4-AMINO-5-FLUORO-PYRIMIDINE DERIVATIVES AS FUNGICIDES | DOW AGROSCIENCES LLC (US) | 2015-08-19 | — | — | EP | disclosed |
| US-20140363369-A1 | PROCESS FOR PRODUCING HYDROGEN OR HEAVY HYDROGENS, AND HYDROGENATION (PROTIATION, DEUTERATION OR TRITIATION) OF ORGANIC COMPOUNDS USING SAME | SHIONO CHEMICAL CO., LTD. (JP) | 2014-12-11 | — | — | US | disclosed |
| US-8871980-B2 | Process for producing hydrogen or heavy hydrogens, and hydrogenation (protiation, deuteration or tritiation) of organic compounds using same | SHIONO CHEMICAL CO., LTD. (JP) | 2014-10-28 | — | — | US | disclosed |
| EP-2607300-A1 | PROCESS FOR PRODUCING HYDROGEN OR HEAVY HYDROGENS, AND HYDROGENATION (PROTIATION, DEUTERATION OR TRITIATION) OF ORGANIC COMPOUNDS USING SAME | Shiono Chemical Co., Ltd. (JP) | 2013-06-26 | — | — | EP | disclosed |
| US-20130150623-A1 | PROCESS FOR PRODUCING HYDROGEN OR HEAVY HYDROGENS, AND HYDROGENATION (PROTIATION, DEUTERATION OR TRITIATION) OF ORGANIC COMPOUNDS USING SAME | SHIONO CHEMICAL CO., LTD. (JP) | 2013-06-13 | — | — | US | disclosed |
| WO-2010076564-A2 | ISOCHROMENONES USEFUL IN THE TREATMENT OF INFLAMMATION | BIOLIPOX AB (SE) | 2010-07-08 | — | — | WO | disclosed |
| WO-2004031149-A1 | SUBSTITUTED GAMMA-PHENYL-DELTA-LACTAMS AND USES RELATED THERETO | INFLAZYME PHARMACEUTICALS LTD. (CA) | 2004-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170152257-A1 | PHENANTHROINDOLIZIDINE AND PHENANTHROQUINOLIZIDINE ALKALOID HAVING A HYDROXYL GROUP ON THE PHENANTHRENE RING THEREOF, PREPARATION METHOD AND USE THEREOF | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, PAH, HIPK4 | PDE4A 2214/4885MAPK1 3795/4885PDE4D 3202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.